Overall survival results from a phase III study of tivozanib hydrochloride versus sorafenib in patients with renal cell carcinoma Meeting Abstract


Authors: Motzer, R. J.; Eisen, T.; Hutson, T. E.; Szczylik, C.; Krygowski, M.; Strahs, A. L.; Esteves, B.; Krivoshik, A. P.; Berkenblit, A.; Nosov, D.
Abstract Title: Overall survival results from a phase III study of tivozanib hydrochloride versus sorafenib in patients with renal cell carcinoma
Meeting Title: 2013 Genitourinary Cancers Symposium
Journal Title: Journal of Clinical Oncology
Volume: 31
Issue: 6 Suppl.
Meeting Dates: 2013 Feb 14-16
Meeting Location: Orlando, FL
ISSN: 0732-183X
Publisher: American Society of Clinical Oncology  
Date Published: 2013-02-20
Language: English
ACCESSION: WOS:000333679600348
PROVIDER: wos
DOI: 10.1200/jco.2013.31.6_suppl.350
Notes: Meeting Abstract: 350 -- Source: Wos
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Robert Motzer
    1243 Motzer